Ammf - The Cholangiocarcinoma Charity

AMMF – The Cholangiocarcinoma Charity, founded in 2002 by Helen Morement as a memorial to her husband Alan who died from this rare bile duct cancer, is the UK's only charity dedicated exclusively to cholangiocarcinoma. Its mission focuses on raising awareness, providing reliable information to patients, families, and clinicians, and funding specialist research to uncover causes, enable earlier diagnosis, improve treatments, and pursue a cure. Guided by compassion, scientific rigor, patient-centered advocacy, and robust governance as a Charitable Incorporated Organisation, AMMF places those affected at the heart of its activities, including national campaigns, conferences uniting researchers and patients, and global collaborations.

It funds targeted cholangiocarcinoma research projects—such as biomarker discovery, novel diagnostics, clinical innovations, and patient outcomes—at universities, hospitals, and specialist institutes. Beneficiaries include researchers, clinical teams, and those directly impacted, with grants supporting direct costs, postdoctoral salaries, and consumables.

Eligible applicants are primarily UK and international academic institutions, NHS trusts, and research bodies with proven capacity; no income thresholds or religious restrictions apply, and geography spans the UK with openness to Europe and beyond for projects benefiting cholangiocarcinoma research. Typical grants range from £17,000 to £100,000 (mostly £20,000–£60,000). Applications follow annual competitive rounds via email—starting with abstracts (e.g., late February) then full proposals (early April)—with the 2025 round closed; check the website for 2026 openings, reviewed by scientific advisors within 2–3 months.

AMMF excludes non-research activities, generic cancer projects, core funding, or clinical care without research ties, distinguishing itself through its singular focus on this unmet need, personal founding story, high-integrity standards, and blend of research investment with patient advocacy.